Scilex Pharms Inc   Report issue

For profit Phase 1 Phase 4
Founded: San Diego CA United States (2011)
Status: Acquired by Sorrento Therapeutics, Inc. (2016)

Organization Overview

First Clinical Trial
2014
NCT04144192
First Marketed Drug
2018
lidocaine (xylocaine)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SCILEX HLDG | Scilex Ltd. | Scilex Pharmaceuticals, Inc. | SCILEX PHARMS | SCILEX PHARMS INC